-
Uncategorized1 month agoSTAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got more...
-
Uncategorized1 month ago
Bayer ends multi-year M&A drought with up to $2.45B Perfuse buy
For $300 million upfront, Bayer is purchasing Perfuse Therapeutics to advance an eye implant for glaucoma and diabetic retinopathy, marking the company’s first pharma acquisition since...
-
Uncategorized1 month ago
Viridian turns green again as new Phase 3 data vindicate thyroid eye disease drug
Viridian Therapeutics’ elegrobart normalized the degree of eye protrusion and improved double vision in a Phase 3 study. The company plans to file for approval in...
-
Uncategorized1 month ago
Novelty Nobility Expands AGC Biologics Deal to Take Product Candidate Through GMP Manufacturing
Korea-based Novelty Nobility expanded its agreement with CDMO AGC Biologics to advance their bispecific antibody drug candidate through process development and GMP manufacturing at AGC Biologics’...
-
Uncategorized1 month ago
J&J pushes dual-antibody IBD therapy into Phase 3 despite mid-stage fails
Johnson & Johnson plans to advance the co-antibody therapy, which combines its IL-23 blocker Tremfya and the TNF-alpha inhibitor Simponi, into late-stage testing for Crohn’s disease...
-
Uncategorized1 month agoHHS tackles ‘overmedication’
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. Are you keeping up with “The...
-
Uncategorized1 month ago
Makary defends Replimune melanoma rejection again as FDA tensions build
Makary defends Replimune melanoma rejection again as FDA tensions build
-
Uncategorized1 month ago
CellCentric raises $220M to get multiple myeloma pill to market
CellCentric has reeled in a massive fund to help it address multiple myeloma patients who have exhausted all other treatment options. The 22-year-old transatlantic biotech has...
-
Uncategorized1 month ago
Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening
First quarter earnings continue to arrive, with analysts demanding more from cautious Pfizer and Eli Lilly expecting more revenue; the FDA taps Katherine Szarama as Vinay...
-
Uncategorized1 month ago
Novo Nordisk’s Q1 in four words: Pills, pricing, payments and pressure
Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure
